269 related articles for article (PubMed ID: 34604048)
1. DNA Damage Response and Repair Gene Alterations Increase Tumor Mutational Burden and Promote Poor Prognosis of Advanced Lung Cancer.
Dai J; Jiang M; He K; Wang H; Chen P; Guo H; Zhao W; Lu H; He Y; Zhou C
Front Oncol; 2021; 11():708294. PubMed ID: 34604048
[TBL] [Abstract][Full Text] [Related]
2. Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy.
Parikh AR; He Y; Hong TS; Corcoran RB; Clark JW; Ryan DP; Zou L; Ting DT; Catenacci DV; Chao J; Fakih M; Klempner SJ; Ross JS; Frampton GM; Miller VA; Ali SM; Schrock AB
Oncologist; 2019 Oct; 24(10):1340-1347. PubMed ID: 31040255
[TBL] [Abstract][Full Text] [Related]
3. DNA damage response and repair gene mutations are associated with tumor mutational burden and outcomes to platinum-based chemotherapy/immunotherapy in advanced NSCLC patients.
Gu W; Zhuang W; Zhuang M; He M; Li Z
Diagn Pathol; 2023 Nov; 18(1):119. PubMed ID: 37924135
[TBL] [Abstract][Full Text] [Related]
4. DNA Damage Response and Repair Pathway Alteration and Its Association With Tumor Mutation Burden and Platinum-Based Chemotherapy in SCLC.
Park S; Lee H; Lee B; Lee SH; Sun JM; Park WY; Ahn JS; Ahn MJ; Park K
J Thorac Oncol; 2019 Sep; 14(9):1640-1650. PubMed ID: 31125737
[TBL] [Abstract][Full Text] [Related]
5. Development and validation of a DNA damage repair-related gene-based prediction model for the prognosis of lung adenocarcinoma.
Qin C; Fan X; Sai X; Yin B; Zhou S; Addeo A; Bian T; Yu H
J Thorac Dis; 2023 Dec; 15(12):6928-6945. PubMed ID: 38249902
[TBL] [Abstract][Full Text] [Related]
6. Alterations of DNA damage response pathway: Biomarker and therapeutic strategy for cancer immunotherapy.
Jiang M; Jia K; Wang L; Li W; Chen B; Liu Y; Wang H; Zhao S; He Y; Zhou C
Acta Pharm Sin B; 2021 Oct; 11(10):2983-2994. PubMed ID: 34729299
[TBL] [Abstract][Full Text] [Related]
7. The effects of altered DNA damage repair genes on mutational processes and immune cell infiltration in esophageal squamous cell carcinoma.
Yuan H; Qing T; Zhu S; Yang X; Wu W; Xu K; Chen H; Jiang Y; Zhu C; Yuan Z; Zhang T; Jin L; Suo C; Lu M; Chen X; Ye W
Cancer Med; 2023 Apr; 12(8):10077-10090. PubMed ID: 36708047
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of tumor mutation burden and DNA damage repair in advanced stage non-small cell lung cancer patients.
Zhang H; Deng YM; Chen ZC; Tang YC; Yang S; Zhang SD; Liang JM; Wang YG; Wu X; Zhang RW; Feng WN
Eur Rev Med Pharmacol Sci; 2020 Jul; 24(14):7664-7672. PubMed ID: 32744692
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive analysis of DNA damage repair deficiency in 10,284 pan-cancer study.
Xiao Y; Lu D; Lei M; Xie W; Chen Y; Zheng Y; Wang C; Zhao J; Zhu Z; Zhao X; Huang M; Lin Y; Li Z; Yang L
Ann Transl Med; 2021 Nov; 9(22):1661. PubMed ID: 34988170
[TBL] [Abstract][Full Text] [Related]
10. Genomic Profiling of Chinese Cervical Cancer Patients Reveals Prevalence of DNA Damage Repair Gene Alterations and Related Hypoxia Feature.
Wen H; Guo QH; Zhou XL; Wu XH; Li J
Front Oncol; 2021; 11():792003. PubMed ID: 35071000
[TBL] [Abstract][Full Text] [Related]
11. Additive effects of variants of unknown significance in replication repair-associated DNA polymerase genes on mutational burden and prognosis across diverse cancers.
Ying J; Yang L; Yin JC; Xia G; Xing M; Chen X; Pang J; Wu Y; Bao H; Wu X; Shao Y; Zhu L; Cheng X
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34479923
[TBL] [Abstract][Full Text] [Related]
12. Deleterious alterations of DNA damage response and repair genes and clinical benefit to anti-PD-1 therapy in esophageal squamous cell carcinoma.
Guo JC; Lin CC; Hsu CL; Huang TC; Kuo HY; Lin CY; Lien MY; Cheng AL; Hsu CH
Esophagus; 2022 Oct; 19(4):693-701. PubMed ID: 35816242
[TBL] [Abstract][Full Text] [Related]
13. DNA damage response alterations in clear cell renal cell carcinoma: clinical, molecular, and prognostic implications.
Jing X; Qin X; Liu H; Liu H; Wang H; Qin J; Zhang Y; Cao S; Fan X
Eur J Med Res; 2024 Feb; 29(1):107. PubMed ID: 38326910
[TBL] [Abstract][Full Text] [Related]
14. The Tumor Mutational Burden of Chinese Advanced Cancer Patients Estimated by a 381-cancer-gene Panel.
Zhuang W; Ma J; Chen X; Wang G; Lu J; Chen Y; Dong H; Cai S; Zhang Y; Zhao X; Zhu Y; Xu C; Huang Y; Huang Z; Zhu X; Jiang H; Wang Z
J Cancer; 2018; 9(13):2302-2307. PubMed ID: 30026825
[No Abstract] [Full Text] [Related]
15. DNA Damage Repair Gene Set as a Potential Biomarker for Stratifying Patients with High Tumor Mutational Burden.
Chiu TY; Lin RW; Huang CJ; Yeh DW; Wang YC
Biology (Basel); 2021 Jun; 10(6):. PubMed ID: 34198473
[TBL] [Abstract][Full Text] [Related]
16. Patient-Level DNA Damage Repair Pathway Profiles and Anti-Tumor Immunity for Gastric Cancer.
Lou S; Wang Y; Zhang J; Yin X; Zhang Y; Wang Y; Xue Y
Front Immunol; 2021; 12():806324. PubMed ID: 35082793
[TBL] [Abstract][Full Text] [Related]
17. Association between DNA damage repair gene somatic mutations and immune-related gene expression in ovarian cancer.
Tian W; Shan B; Zhang Y; Ren Y; Liang S; Zhao J; Zhao Z; Wang G; Zhao X; Peng D; Bi R; Cai S; Bai Y; Wang H
Cancer Med; 2020 Mar; 9(6):2190-2200. PubMed ID: 31991061
[TBL] [Abstract][Full Text] [Related]
18. DNA damage repair pathway alterations in metastatic clear cell renal cell carcinoma and implications on systemic therapy.
Ged Y; Chaim JL; DiNatale RG; Knezevic A; Kotecha RR; Carlo MI; Lee CH; Foster A; Feldman DR; Teo MY; Iyer G; Chan T; Patil S; Motzer RJ; Hakimi AA; Voss MH
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32571992
[TBL] [Abstract][Full Text] [Related]
19. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of DNA damage response mutations in stage I and stage IIIa NSCLC.
Zhang H; Zhang D; Liu J; Shi Y; Liu X; Chen M; Zhong W; Zhao J; Xu Y; Wang M
Thorac Cancer; 2023 Nov; 14(32):3191-3201. PubMed ID: 37704455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
